- Title
- The TETAMI Trial : The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed : Methods and design
- Creators
- Marc Cohen - Hahnemann University HospitalFrans Maritz - Karl Bremer HospitalVeronique LE-LOUER - Aventis PharmaFrederique Bigonzi - Aventis PharmaGian Franco Gensini - AngiologicaNicolas Danchin - Brabois Vandoeuvre, FranceAri Timerman - Instituto Dante Pazzanese de CardiologiaKurt Huber - University of ViennaEnrique P Gurfinkel - Fundación FavaloroHarvey White - Green Lane Hospital, Auckland, New ZealandKeith A. A Fox - Edinburgh Royal InfirmaryLuc Vittori - Aventis PharmaHoward Dalby White - [Retired Faculty]
- Publication Details
- Journal of thrombosis and thrombolysis, v 10(3), pp 241-246
- Publisher
- Springer
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- [Retired Faculty]
- Web of Science ID
- WOS:000166045300006
- Scopus ID
- 2-s2.0-17744384489
- Other Identifier
- 991019168638204721
Journal article
The TETAMI Trial : The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed : Methods and design
Journal of thrombosis and thrombolysis, v 10(3), pp 241-246
2000
PMID: 11122544
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Metrics
Details
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Cardiac & Cardiovascular Systems
- Hematology
- Peripheral Vascular Disease